Syncromune® Inc. to Present Clinical Data from SYNC-T Therapy SV-102 Phase 1 Trial at the American Society for Clinical Oncology Annual Meeting 2025 Posted April 25, 2025
Syncromune Appoints Zhihong Li, Ph.D., as Chief Regulatory Affairs Officer to Lead Global Regulatory Strategy for Novel Oncology Immunotherapies Posted March 25, 2025
Syncromune Granted FDA Fast-Track Designation for SYNC-T™ SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Posted July 1, 2024
Syncromune® Inc. Announces FDA Clearance of IND Application for SYNC-T™ SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer Posted May 30, 2024
Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024 Posted April 8, 2024
Syncromune® Inc. to Present Initial Clinical Data from SYNC-T™ SV-102 Phase 1 as a Late-Breaker at the American Association for Cancer Research Annual Meeting 2024 Posted March 6, 2024
Syncromune® Inc. Expands Scientific Advisory Board with Addition of Prominent Oncology Trailblazer James Armitage, M.D. Posted October 31, 2023
Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies Posted August 30, 2023
Syncromune® Inc., Appoints Jonathan Lewis, M.D., Ph.D., A Renowned Immune Therapy Pioneer, as Chief Medical Officer Posted July 12, 2023
